ArriVent BioPharma, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from ArriVent BioPharma, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Debt Due Cover Ratio: Operating cash was negative last year, while some debt falls due within a year. Lower than almost all Healthcare companies in United States.
- Steadiness Ratio: Sales and profit both fell in each of the last 3 years. Less steady than 96% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 0/3Sales and profit both fell in each of the last 3 years.
Less steady than 96% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-11,470.6×Operating cash was negative last year, while some debt falls due within a year.
Lower than almost all Healthcare companies in United States.
Cash Cushion Ratio
+33%Cash, after subtracting all debt, equals 33% of its market value (net cash).
Higher than 70% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (10)
ArriVent BioPharma, Inc. made a loss over the last year. ArriVent BioPharma, Inc. owes $0.07 for every $1 it owns. ArriVent BioPharma, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossArriVent BioPharma, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
2.58The share price is 2.58 times ArriVent BioPharma, Inc.'s book value per share, higher than 50% of Healthcare companies in United States.
Market cap
$947 MThe total market value of all of ArriVent BioPharma, Inc.'s shares at today's price (share price × number of shares), larger than 63% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$367 MWhat ArriVent BioPharma, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$7.44Net worth divided by the number of shares. The share price of $19.20 is 2.6 times this, which is the P/B above.
Return on equity (ROE)
-53.2%ArriVent BioPharma, Inc. lost 53.2% of its shareholders' money over the last year, lower than 53% of Healthcare companies in United States.
Owes vs Owns
0.07×ArriVent BioPharma, Inc. owes $0.07 for every $1 it owns (low), lower than 92% of Healthcare companies in United States.
Dividend yield
NoneArriVent BioPharma, Inc. does not currently pay a dividend.
Profit growth
LossArriVent BioPharma, Inc. made a loss in each of the last two years.
Cash vs debt
Net cashArriVent BioPharma, Inc. held $313 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For ArriVent BioPharma, Inc.: $947 M ÷ $367 M (30 Jun 2026) = 2.6.
What is ArriVent BioPharma, Inc.'s return on equity?
ArriVent BioPharma, Inc. lost 53.2% of its shareholders' money over the last year, lower than 53% of Healthcare companies in United States.
How much does ArriVent BioPharma, Inc. owe compared with what it owns?
ArriVent BioPharma, Inc. owes $0.07 for every $1 it owns (low), lower than 92% of Healthcare companies in United States.
Does ArriVent BioPharma, Inc. pay a dividend?
No. ArriVent BioPharma, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.